Chemokine MCP-1/CCL-2: A Promising Biomarker to Differentiate Severe and Non-Severe Malaria?

Malaria, an endemic disease affecting nearly 249 million people annually, remains a global public health priority. Given the limitations of current diagnostic methods, the search for new effective biomarkers to distinguish severe from non-severe cases has become critical. In this context, MCP-1/CCL-2, a key chemokine in the inflammatory response, has emerged as a potential candidate for disease diagnosis and severity assessment.

This study was initiated to evaluate whether MCP-1/CCL-2 could be a reliable marker for diagnosing malaria and determining its severity.